论文部分内容阅读
目的:探讨心力衰竭(心衰)患者血清半乳凝集素(Galectin)-3表达水平与心脏结构、功能的关系,并评估其对预后的预测价值。方法:选取76例NYHA分级为Ⅰ～Ⅳ级的患者,测定血清Galectin-3及氨基末端脑钠肽前体水平、心脏超声。出院60d内电话随访,记录死亡及再入院等心脏不良事件。结果:NYHAⅠ级、Ⅱ级、Ⅲ～Ⅳ级患者血Galectin-3分别为(4.41±1.12)、(6.45±1.56)、(8.82±3.78)ng/ml,两两比较均差异有统计学意义(P<0.05)。Galectin-3与NYHA分级(r=0.44,P<0.05)、左室舒张末期内径(r=0.41,P<0.05)均呈正相关。60d内发生心脏不良事件患者的血Galectin-3水平明显高于未发生心脏不良事件的患者[(8.14±1.29)ng/ml∶(6.86±3.14)ng/ml,P<0.05]。结论:Galectin-3水平与心衰严重程度及左室重构相关。Galectin-3水平升高的患者近期预后差。
Objective: To investigate the relationship between serum galectin-3 expression and cardiac structure and function in patients with heart failure (CHF) and to evaluate its prognostic value. Methods: Seventy-six patients with NYHA class Ⅰ-Ⅳ were enrolled in this study. Serum levels of Galectin-3 and N-terminal pro-brain natriuretic peptide were measured. Echocardiography was performed. Telephone follow-up within 60 days after discharge was recorded, and cardiac adverse events such as death and re-admission were recorded. Results: The levels of Galectin-3 in NYHA class Ⅰ, Ⅱ and Ⅲ ~ Ⅳ were (4.41 ± 1.12), (6.45 ± 1.56) and (8.82 ± 3.78) ng / ml, P <0.05). Galectin-3 was positively correlated with NYHA classification (r = 0.44, P <0.05) and left ventricular end diastolic diameter (r = 0.41, P <0.05). The level of Galectin-3 in patients with cardiac events within 60 days was significantly higher than those in patients without cardiac adverse events (8.14 ± 1.29 ng / ml vs 6.86 ± 3.14 ng / ml, P <0.05). Conclusion: The level of Galectin-3 correlates with the severity of heart failure and left ventricular remodeling. Patients with elevated Galectin-3 have a near-term poor prognosis.